IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i12d10.1007_s40264-024-01471-z.html
   My bibliography  Save this article

Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

Author

Listed:
  • Michele Fusaroli

    (University of Bologna)

  • Stefano Polizzi

    (University of Bologna)

  • Luca Menestrina

    (Alma Mater Studiorum-University of Bologna)

  • Valentina Giunchi

    (University of Bologna)

  • Luca Pellegrini

    (Hertfordshire Partnership NHS University Foundation Trust, Highly Specialised OCD and BDD Service
    University of Hertfordshire)

  • Emanuel Raschi

    (University of Bologna)

  • Daniel Weintraub

    (University of Pennsylvania
    Philadelphia Veterans Affairs Medical Center)

  • Maurizio Recanatini

    (Alma Mater Studiorum-University of Bologna)

  • Gastone Castellani

    (University of Bologna)

  • Fabrizio Ponti

    (University of Bologna)

  • Elisabetta Poluzzi

    (University of Bologna)

Abstract

Introduction Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice. Objective This study explores the syndromic burden of impulsivity induced by pramipexole and aripiprazole, pinpointing key symptoms for targeted mitigation. Methods An event-event Information Component (IC) on the FDA Adverse Event Reporting System (FAERS) (January 2004 to March 2022) identified the syndrome of events disproportionally co-reported with impulsivity, separately for pramipexole and aripiprazole. A greedy-modularity clustering on composite network analyses (positive pointwise mutual information [PPMI], Ising, Φ) identified sub-syndromes. Bayesian network modeling highlighted possible precipitating events. Results Suspected drug-induced impulsivity was documented in 7.49% pramipexole and 4.50% aripiprazole recipients. The highest IC concerned obsessive-compulsive disorder (reporting rate = 26.77%; IC median = 3.47, 95% confidence interval [CI] = 3.33–3.57) and emotional distress (21.35%; 3.42, 3.26–3.54) for pramipexole, bankruptcy (10.58%; 4.43, 4.26–4.55) and divorce (7.59%; 4.38, 4.19–4.53) for aripiprazole. The network analysis identified delusional jealousy and dopamine dysregulation sub-syndromes for pramipexole, obesity-hypoventilation and social issues for aripiprazole. The Bayesian network highlighted anxiety and economic problems as potentially precipitating events. Conclusion The under-explored consequences of drug-induced impulsivity significantly burden patients and families. Network analyses, exploring syndromic reactions and potential precipitating events, complement traditional techniques and clinical judgment. Characterizing the secondary impact of reactions will support informed patient-centered decision making.

Suggested Citation

  • Michele Fusaroli & Stefano Polizzi & Luca Menestrina & Valentina Giunchi & Luca Pellegrini & Emanuel Raschi & Daniel Weintraub & Maurizio Recanatini & Gastone Castellani & Fabrizio Ponti & Elisabetta , 2024. "Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System," Drug Safety, Springer, vol. 47(12), pages 1275-1292, December.
  • Handle: RePEc:spr:drugsa:v:47:y:2024:i:12:d:10.1007_s40264-024-01471-z
    DOI: 10.1007/s40264-024-01471-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-024-01471-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-024-01471-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:12:d:10.1007_s40264-024-01471-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.